Literature DB >> 17974865

Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older.

Jean Hollis1, David Grayson, Loelle Forrester, Henry Brodaty, Stephen Touyz, Robert Cumming.   

Abstract

OBJECTIVE: To establish the instantaneous relative risk (RR) of death associated with individual antipsychotic drugs, carbamazepine and sodium valproate for those 65 years and older.
METHODS: Subjects dispensed antipsychotic drugs, sodium valproate or carbamazepine in 2003 or 2004 were analyzed as incident (N = 16,634) or prevalent (N = 9,831) users. Survival curves, mortality rates, and Cox proportional hazards models over two time periods were used to explore risk of death. The models were adjusted for age, sex, residential status, and psychotropic and medical drug dispensing. Olanzapine subjects were the reference group in the Cox regression. Subanalyses were performed for incident subjects with more than 30 days of follow-up and those dispensed cholinesterase inhibitors.
RESULTS: In the adjusted Cox proportional hazards models, haloperidol dispensing was consistently associated with an increased risk of death compared with olanzapine users (relative risk [RR] for incident users: 2.26, 95% confidence intervals (CI): 2.08-2.47; Wald statistic: 345.36, df = 1, p < or =0.001). There was some evidence of decreased survival with dispensing of higher haloperidol doses, although confounding by medical comorbidity cannot be excluded. Chlorpromazine (RR: 1.39, 95% CI: 1.15-1.67; Wald statistic: 12.08, df = 1, p <0.001) and risperidone (RR: 1.23, 95% CI: 1.07-1.40; Wald statistic: 9.12, df = 1, p = 0.003) dispensing were associated with increased risk of death in incident users.
CONCLUSION: These results should be interpreted cautiously because haloperidol and chlorpromazine are used in broader clinical contexts. However, in the absence of data from randomized trials, the safety profile of haloperidol should not be assumed to be benign. Antipsychotic drugs should not be studied as an aggregated group because their associated risks are not uniform.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17974865     DOI: 10.1097/JGP.0b013e31813547ca

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  11 in total

1.  Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series.

Authors:  Nicole L Pratt; Elizabeth E Roughead; Emmae Ramsay; Amy Salter; Philip Ryan
Journal:  Drugs Aging       Date:  2010-11-01       Impact factor: 3.923

Review 2.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

3.  Sedative load and mortality among residents of long-term care facilities: a prospective cohort study.

Authors:  Heidi T Taipale; J Simon Bell; Helena Soini; Kaisu H Pitkälä
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

4.  All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study.

Authors:  Rosa Liperoti; Graziano Onder; Francesco Landi; Kate L Lapane; Vincent Mor; Roberto Bernabei; Giovanni Gambassi
Journal:  J Clin Psychiatry       Date:  2009-10       Impact factor: 4.384

5.  Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities.

Authors:  Linda Simoni-Wastila; Priscilla T Ryder; Jingjing Qian; Ilene H Zuckerman; Thomas Shaffer; Lirong Zhao
Journal:  Am J Geriatr Psychiatry       Date:  2009-05       Impact factor: 4.105

Review 6.  Management of agitation and aggression associated with Alzheimer disease.

Authors:  Clive G Ballard; Serge Gauthier; Jeffrey L Cummings; Henry Brodaty; George T Grossberg; Philippe Robert; Constantine G Lyketsos
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

7.  Sudden death in patients receiving drugs tending to prolong the QT interval.

Authors:  Kate Jolly; Michael D Gammage; Kar Keung Cheng; Peter Bradburn; Miriam V Banting; Michael J S Langman
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

8.  Treatment of behavioral and psychological symptoms of Alzheimer's disease.

Authors:  Anne Corbett; Jessica Smith; Byron Creese; Clive Ballard
Journal:  Curr Treat Options Neurol       Date:  2012-04       Impact factor: 3.598

Review 9.  Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review.

Authors:  Nicole Pratt; Elizabeth E Roughead; Amy Salter; Philip Ryan
Journal:  BMC Med Res Methodol       Date:  2012-06-08       Impact factor: 4.615

10.  Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials.

Authors:  M Seibert; V Mühlbauer; J Holbrook; S Voigt-Radloff; S Brefka; D Dallmeier; M Denkinger; C Schönfeldt-Lecuona; S Klöppel; C A F von Arnim
Journal:  Alzheimers Res Ther       Date:  2021-07-16       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.